Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

BioPharma Terug naar discussie overzicht

NPS PHARM INC (NPSP)

3 Posts
| Omlaag ↓
  1. [verwijderd] 9 oktober 2007 16:53
    AP
    NPS Ends AstraZeneca Collaboration
    Tuesday October 9, 10:40 am ET
    NPS Pharmaceuticals Gets $30 Million After Ending MGluRs AstraZeneca Drug Development Pact

    BEDMINSTER, N.J. (AP) -- Shares of drug developer NPS Pharmaceuticals Inc. rose sharply Tuesday after the company said it ended a six-year partnership to develop drugs targeting metabotropic glutamate receptors with AstraZeneca.

    ADVERTISEMENT
    The collaboration focused on developing central nervous system disorder treatments. NPS said the companies have generated several drug candidates for preclinical and early-stage development.

    NPS will no longer provide research support or maintain interests in any drugs developed and marketed under the program. The company will instead focus on its late-stage pipeline products, including osteoporosis drug Preos and gastrointestinal disorders drug Gattex.

    AstraZeneca will pay $30 million to acquire NPS's assets related to their research agreement.

    "This strategic move creates investment flexibility for NPS and enables us to use the monies from this deal, the previously announced Nycomed Gattex deal and the approximately $10 million in savings over the next two years from this transaction to support the further development of our late-stage pipeline products," said Tony Coles, president and CEO of NPS.

    Shares of NPS rose 74 cents, or 15.6 percent, to $5.50 in morning trading. Shares of AstraZeneca fell 50 cents to $51.76 in morning trading.

    Laatste koers Verschil
    5.63 USD 0.87 (18.28 %)


3 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.017
AB InBev 2 5.496
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.634
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.639
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.749
Aedifica 3 916
Aegon 3.258 322.817
AFC Ajax 538 7.088
Affimed NV 2 6.296
ageas 5.844 109.891
Agfa-Gevaert 14 2.050
Ahold 3.538 74.335
Air France - KLM 1.025 35.043
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.791
Allfunds Group 4 1.471
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 243.131
AMG 971 133.317
AMS 3 73
Amsterdam Commodities 305 6.689
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 14.998
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.775
Arcelor Mittal 2.033 320.701
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.300
Aroundtown SA 1 219
Arrowhead Research 5 9.735
Ascencio 1 27
ASIT biotech 2 697
ASMI 4.108 39.096
ASML 1.766 107.082
ASR Nederland 21 4.484
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.667
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392

Macro & Bedrijfsagenda

  1. 21 februari

    1. Duitse verkiezingen (op 23 februari)
    2. Inflatie januari (Jap)
    3. Samengestelde inkoopmanagersindex februari (Jap)
    4. Investeringen december (NL)
    5. Prijzen bestaande koopwoningen januari (NL)
    6. Heijmans Q4-cijfers
    7. Cofinimmo Q4-cijfers
    8. Brunel Q4-cijfers
    9. Detailhandelsverkopen januari (VK)
    10. Samengestelde inkoopmanagersindex februari (Fra)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht